Skip to main content

Keloid

2
Pipeline Programs
6
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
2100%
+ 5 programs with unclassified modality

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
1
BleomycinPhase 41 trial
Active Trials
NCT04582305Unknown14Est. Mar 2023
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
1
68Ga-FAPIPhase 1/21 trial
Active Trials
NCT05275699Completed25Est. Feb 2023
Regeneron
RegeneronTARRYTOWN, NY
2 programs
DupilumabPHASE_2Monoclonal Antibody1 trial
DupilumabPHASE_4Monoclonal Antibody
Active Trials
NCT05128383Completed20Est. Jun 2025
Labcorp
LabcorpBURLINGTON, NC
1 program
Autologous Platelet Rich Plasma obtained with RegenKit®-BCTN/A
Regen Lab
Regen LabSwitzerland - Le Mont-sur-Lausanne
1 program
Autologous Platelet Rich Plasma obtained with RegenKit®-BCTN/A1 trial
Active Trials
NCT02922972Completed15Est. Sep 2017
Organogenesis
OrganogenesisCANTON, MA
1 program
ApligrafPHASE_1_21 trial
Active Trials
NCT00587587Completed30Est. Mar 2010

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Human BioSciencesBleomycin
RegeneronDupilumab
UNION therapeutics68Ga-FAPI
OrganogenesisApligraf
Regen LabAutologous Platelet Rich Plasma obtained with RegenKit®-BCT

Clinical Trials (5)

Total enrollment: 104 patients across 5 trials

NCT04582305Human BioSciencesBleomycin

Bleomycin Jet Injections in Keloids

Start: Mar 2022Est. completion: Mar 202314 patients
Phase 4Unknown
NCT05128383RegeneronDupilumab

Study to Assess Efficacy and Safety of Dupilumab in the Treatment of Keloids

Start: Jan 2023Est. completion: Jun 202520 patients
Phase 2Completed
NCT05275699UNION therapeutics68Ga-FAPI

Analyse of Diagnosis Value of Keloid on 68Ga- FAPI-04 PET-CT

Start: Mar 2022Est. completion: Feb 202325 patients
Phase 1/2Completed
NCT00587587OrganogenesisApligraf

A Pilot Study of Apligraf for the Treatment and Prevention of Recurrence of Excised Keloids

Start: Dec 2007Est. completion: Mar 201030 patients
Phase 1/2Completed
NCT02922972Regen LabAutologous Platelet Rich Plasma obtained with RegenKit®-BCT

Treatment of Keloid Scar by Autologous Platelet Rich Plasma Obtained With RgenKit-BCT

Start: Sep 2014Est. completion: Sep 201715 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.